Table 3.
Weight change (kg) from pre-medication baseline, for both the total sample and for abstainers only, at EOT and 48-weeks post-TQD. All comparisons are relative to placebo. Values are presented as least square means (standard error).
| Study | Placebo | 5 mg | 20 mg | |||
|---|---|---|---|---|---|---|
| EOT (8 weeks post-TQD) | ||||||
| STRATUS EU | 1.70 | (0.17) | 0.86 | (0.17)** | −0.06 | (0.16)*** |
| Abstainers only | 2.61 | (0.33) | 1.72 | (0.30)* | 0.42 | (0.28)** |
| STRATUS US | 2.00 | (0.18) | 1.45 | (0.18)* | 0.35 | (0.17)*** |
| Abstainers only | 3.51 | (0.38) | 2.32 | (0.39)* | 0.90 | (0.30)*** |
| STRATUS META | 1.82 | (0.21) | - | - | −0.10 | (0.19)*** |
| Abstainers only | 2.64 | (0.47) | - | - | 1.62 | (0.36) |
| POOLED EU/US | 1.84 | (0.12) | 1.14 | (0.12)** | 0.14 | (0.12)*** |
| Abstainers only | 3.04 | (0.25) | 2.03 | (0.24)** | 0.66 | (0.21)*** |
| POOLED EU/US/META | 1.76 | (0.11) | - | - | −0.01 | (0.10)*** |
| Abstainers only | 3.03 | (0.23) | - | - | 0.92 | (0.19)*** |
| 48 Weeks (Post-TQD) | ||||||
| STRATUS EU | 3.27 | (0.37) | 3.33 | (0.36) | 3.24 | (0.36) |
| Abstainers only | 4.94 | (0.74) | 5.56 | (0.72) | 4.72 | (0.68) |
| STRATUS US | 3.17 | (0.45) | 4.43 | (0.44)* | 3.92 | (0.41) |
| Abstainers only | 7.35 | (1.31) | 7.13 | (1.31) | 5.09 | (0.97) |
| POOLED EU/US | 3.16 | (0.29) | 3.85 | (0.28) | 3.58 | (0.27) |
| Abstainers only | 6.04 | (0.70) | 6.31 | (0.69) | 4.89 | (0.58) |
Note:
*
p < .05,
**
p < .001,
***
p < .0001.
EOT = end of treatment; TQD = targeted quit date.